Bioactive Libraries
Diversity Libraries
Description
Represents the diversity of structures and molecular targets of all FDA-approved chemical entities (Nat Chem Biol 13 (2017), 771–778)
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Description
Most relevant selection of drugs in one formulation/no duplicates. Contains WHO List of Essential Medicines including Lapatinib and latest approved drugs such as Tivozanib, etc.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Description
Actives with extensive target classes’ coverage and the broadest possible therapeutic areas applications – from CNS agents and anti-infectives to anticancer drugs, steroids and molecular glues.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Description
Library of cell penetrated compounds and their closest analogs. Covers diverse therapeutic areas from antitumor, neurology and antibacterial to aging diseases.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Description
Frequent hitters with most diverse scaffold selection – from small hydroquinone and other covalent modifiers to polyfluorinated highly lipophilic molecules and dyes.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Focused Sets
Angiogenesis
184 compounds
Description
Angiogenesis related ligands targeting FLT3, DYRK1A, Collagenase 3, GAK, Bcr-Abl, BTK, EGFR etc.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Apoptosis
38 compounds
Description
Apoptosis related ligands targeting Mdm2 Mcl-1 IAP Caspase Modulator I, Caspase 3 and Caspase 6, Bcl-2, p53, TNF-alpha.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Cancer Immunology
390 compounds
Description
Molecules used for immune-oncology research targeting P2X3 receptor MAG lipase, PI3 kinase and P2Y12.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Cell Cycle
94 compounds
Description
Сell cycle related compounds, e.g. LDC000067 CDK12-In-2 and Palbociclib selective and pan-CDK inhibitors, ROCK, mTOR and Aurora kinase inhibitors.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Epigenetics
158 compounds
Description
Epigenetics related compounds targeting HDACs, HMT, JMJD, DNMT, Bromodomains, i KDM5 inhibitors and Sirtuin.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
GPCRs
738 compounds
Description
Bioactive GPCR-targeted molecules, including GPCR inhibitors, agonists, and allosteric modulators. Library represents actives against 195 unique GPCR targets.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Growth Factors Cytokines
130 compounds
Description
Growth factors and cytokines ligands, including Ceritinib ALK inhibitor, Lucitanib VEGFR and FGFR inhibitor, MSX-127 CXCR4 antagonist, Eltrombopag Thrombopoietin receptor agonist etc.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Ion Channels
300 compounds
Description
Ligands with annotated activity against 6 ion channel families and 105 unique targets. The library covers major applications typical for ion channel: cardiovascular regulation, neuroscience, immune response regulation.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
JAK-STAT
104 compounds
Description
JAK-STAT signalling targeted molecules, including Pazopanib multi-TK inhibitor, LY294002 TPK inhibitor, PF06700841 JAK1 inhibitor, SH-4-54 STAT3 inhibitor and other related actives.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Kinases
366 compounds
Description
Kinase binders, including approved drugs Imatinib, covalent Ibrutinib, Dasatinib and highly active inhibitors of most important kinases such as RAF, MAPK, BTK and many other.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Membrane Receptors
745 compounds
Description
Membrane receptors ligands, including Risperidone (5-HT2 receptor blocker, D2 receptor antagonist), VU0071063 (ATP-dependent potassium channel activator), CU-T12-9 (TLR1/2 antagonist), LY354740 (mGlu2/3 receptor agonist).
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Nuclear Hormone Receptors
160 compounds
Description
Nuclear receptor ligands with referenced activity against 368 unique molecular targets, including agonists Dienogest, antagonists Darolutamide, inverse antagonists GSK805.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Protease Inhibitors
175 compounds
Description
High activity ligands against 104 human and pathogenic proteases, including Saxagliptin, anti-diabetic type 2 drug, Mpro SARS-CoV-2 inhibitors, Atazanavir HIV-1 protease inhibitor etc.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Signal Transduction
254 compounds
Description
Signal transduction related ligands, including Selatinib EGFR/HER-2 inhibitor, XAV-939 Tankyrase1/2 inhibitor, STING agonist-1 G10, Fedratinib broad spectrum kinase inhibitor etc.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
Transporters
169 compounds
Description
Molecules with annotated activity against 12 transporter families and 82 unique targets, including Paroxetine (serotonin reuptake inhibitor), ML-352 (choline transporter 1 inhibitor, AR- C155858 (MCT1 and MCT2 inhibitor, GABA receptor ligands etc.
Price
This email address is being protected from spambots. You need JavaScript enabled to view it.
